Canadian Journal of Physiology and Pharmacology · 2018 · 13 citations · 32 references
MedicineEndocrinologyPharmacologyDiabetologyMetabolic RegulationMolecular PharmacologyAdipose TissueDiabetes MellitusDiabetes PharmacotherapyInsulin ResistanceMetabolic SyndromeOral Antidiabetic AgentsAdipose Tissue DysfunctionBlood Glucose CorrectionBlood Glucose RegulationBody Mass ChangeInsulin Resistance AssessmentLipid Profile ChangesLipid Profile EffectsOral Antidiabetic Medications
Many adipocytokines correlate with obesity and insulin resistance. We examined the effects of metformin, sitagliptin, and liraglutide in diabetic rats. Group 1: control normal (CN) rats received oral saline daily. Group 2: diabetic non-treated (DNT) rats were injected with streptozotocin (STZ) to get diabetic then after 72 h received oral saline daily. Group 3: rats were injected with STZ then after 72 h were treated with metformin (200 mg/kg) orally. Group 4: rats were injected with STZ then after 72 h received sitagliptin 6 mg/kg orally twice daily. Group 5: rats were injected with STZ then after 72 h were treated with liraglutide at a dose of 0.3 mg/kg every 12 h subcutaneous injection. After 8 weeks, body mass, fasting blood glucose, adipocytokines, and lipid profile were assessed. From the results, we concluded that the 3 drugs improved blood glucose and insulin resistance with correction of adipocytokines serum levels; however, the liraglutide-treated group was the only group that showed significant body mass reduction.
32
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Qin Yang, Timothy E. Graham, Nimesh Mody et al. · Nature · 2005 · 2.1K citations